The highly specific MET inhibitor capmatinib may be a new therapeutic option for patients with MET exon 14-mutated or MET-amplified non-small-cell lung cancer (NSCLC), the phase II GEOMETRY mono-1 study has shown.
More than 9 months into the combat against COVID-19, the world has seen battles being stepped up on all fronts in the search for an effective therapy. While new drugs are being developed, old drugs are repurposed as potential treatment for COVID-19, and a plethora others are upcoming in the pipeline.
Having vaccination against influenza during pregnancy was not associated with an increased risk of autism spectrum disorder (ASD) in the offspring, a large cohort study reveals — providing more support for vaccination during pregnancy.
Use of the laryngeal tube (LT) for out-of-hospital cardiac arrest (OHCA) by paramedics in Singapore leads to poorer placement success and more complications as compared with laryngeal mask airway (LMA), a study has found.
The novel, next-generation, highly potent and selective RET inhibitor selpercatinib may modify the landscape of another genomic subgroup — RET-altered cancers, according to two early-phase trials investigating the potential of selpercatinib in medullary thyroid cancer (MTC) and non-small-cell lung cancer (NSCLC).